Newsroom | 12737 results

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the second quarter ended June 30, 2025. “In the second quarter of 2025, AVMAPKI FAKZYNJA CO-PACK became the first-ever treatment approved by the FDA specifically for use in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, and we are of...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 s...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the second quarter ending June 30, 2025. “The second quarter of 2025 marked an important inflection point for Rocket as we refined our strategic focus around our AAV cardiovascular gene therapy platform and took m...

TORONTO--(BUSINESS WIRE)--ProteinQure, a leader in computational protein drug discovery, today announced it has received regulatory clearance from both the U.S. Food and Drug Administration (FDA) and Health Canada to initiate a Phase I clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of its lead candidate, PQ203. The FDA has also granted PQ203 Fast Track designation for patients with triple negative breast cancer, recognizing the therapy’s potent...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, l’impresa che ha creato il sistema di istotripsia Edison® e l’innovativa piattaforma per la terapia con questa tecnica, oggi ha annunciato l’acquisizione della partecipazione di maggioranza guidata dal management da parte di un consorzio di investitori pubblici e privati rinomati globalmente – K5 Global, Bezos Expeditions e Wellington Management nonché altri investitori preesistenti e nuovi. L’operazione assegna a HistoSonics un valore di circa 2,25 mi...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, Entwickler des Edison® Histotripsy-Systems und einer neuartigen Histotripsy-Therapieplattform, gab heute bekannt, dass eine Gruppe weltweit anerkannter privater und öffentlicher Investoren, darunter K5 Global, Bezos Expeditions, Wellington Management sowie weitere neue und bestehende Investoren, unter Führung des Managements eine Mehrheitsbeteiligung erworben hat. Die Transaktion bewertet HistoSonics mit rund 2,25 Mrd. USD und versetzt das Unternehmen...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, de ontwikkelaar van het Edison® histotripsy-systeem en een nieuw histotripsy-behandelplatform, heeft vandaag bekendgemaakt dat een consortium van wereldwijd erkende particuliere en publieke investeerders, waaronder K5 Global, Bezos Expeditions, Wellington Management en andere nieuwe en bestaande investeerders, een meerderheidsbelang in het bedrijf heeft verworven. Met de transactie die HistoSonics op ongeveer 2,25 miljard dollar waardeert, kan het bedr...

MINNEÁPOLIS--(BUSINESS WIRE)--HistoSonics, desarrollador del sistema de histotricia Edison® y de la novedosa plataforma de terapia de histotricia, ha anunciado hoy la adquisición de una participación mayoritaria liderada por la dirección de un sindicato de inversores privados y públicos reconocidos en todo el mundo, incluyendo K5 Global, Bezos Expeditions, Wellington Management y otros inversores nuevos y existentes. La transacción otorga a HistoSonics un valor aproximado de 2250 millones de dó...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, développeur de l’Edison® Histotripsy System et d’une nouvelle plateforme de thérapie histotripsique, a annoncé aujourd’hui l’acquisition d’une participation majoritaire par un consortium d’investisseurs privés et publics de renommée mondiale, dont K5 Global, Bezos Expeditions, Wellington Management et d’autres investisseurs nouveaux et existants. Cette transaction valorise HistoSonics à environ 2,25 milliards de dollars et positionne l’entreprise pour...